Page 734«..1020..733734735736..740750..»

Volunteers: The Flagler Health Departments Secret Weapon in an Epic Covid Fight – FlaglerLive.com

Posted: June 6, 2021 at 2:10 am

The phrase it takes a village is particularly true with respect to Flagler Countys Covid response.

Last week, the Florida Department of Health in Flagler County closed its drive-through operation at the Flagler County Fairgrounds, a site it had staffed for testing and vaccinations several days a week since the middle of 2020. Starting last Jan. 2, the vaccination drive-through required a staff of 50, split between employees and volunteers, resulting in 5,113 volunteer hours logged as part of this local pandemic response.

There is tremendous historical significance to the pandemic. Years from now, everyone involved with the pandemic response will have quite a story to share with their grandchildren and great-grandchildren. The Flagler Health Department is grateful to all the volunteers who have donated their time and effort in reducing Covid infections and encouraging vaccinations in Flagler County. With any luck, these volunteers wont reflect upon the polarized opinions about mask wearing or political divisiveness.

Instead, they will remember the role they played getting people through a global pandemic. Theyll remember the camaraderie of working through rain, cold, and heat, regulating traffic, answering questions, encouraging a smile, calming nerves, and celebrating a first dose of vaccine. Theyll remember doing something important and something that felt right helping the community get past Covid and onto whatever our post-Covid world would be.

To share additional insight of what it meant to be part of the local Covid response from a volunteer perspective, we offer you three interviews: one from Flagler Volunteer Services Judy Mazzella, another from Moya Thompson, and a third from Dr. Stephen Playe, a retired emergency physician.

Meet Judy Mazzella

Two key players in this herculean volunteer effort have been Suzy Gamblain and Judy Mazzella of Flagler Volunteer Services. This team has orchestrated the boots on the ground for more than a year now, coordinating, screening, and scheduling a revolving crew of approximately 110 volunteers to help. At first it was all about community testing for Covid. It then expanded to large-scale vaccination events at the Flagler County Fairgrounds several days a week.

Reflecting over the past nine-plus months, Judy Mazzella describes it as an amazing experience for her agency and the volunteers involved.

Its really been a labor of love to keep our community safe, said Mazzella. Early on, it was about getting people get tested. We spent hundreds of hours working with the health department and Flagler Countys Department of Emergency Management at the first large-scale testing site at Daytona State Colleges Palm Coast campus. In January 2021, we transitioned to a new home at the Flagler County Fairgrounds and other locations throughout the county to help people get vaccinated. On any given day I could expect 20 to 24 volunteers to help with clerical and traffic duty. It took a lot of scheduling and coordination, but the volunteers came back day after day and week after week. Its apparent they really enjoyed being part of the effort and knowing how much they are appreciated.

At its peak, the operation at the fairgrounds could vaccinate about 200 people per hour, an impressive rate reflecting an efficient operation.

In Judys opinion, the camaraderie and friendships that blossomed between volunteers over time encouraged them to come back. Some met through Facebook, interacting online, sharing testing and vaccination information, dispelling myths, supporting the health departments efforts and ultimately signing up to volunteer. Husbands recruited wives, wives recruited husbands. Couples recruited other couples, building an extended family, forming new friendships and making the entire experience more rewarding.

Responding to a global pandemic is serious work. But Flaglers volunteers found ingenious ways to add levity to make the vaccination site a friendly place to work and visit. Crazy hat days, costumes, cardboard cutouts and dancing while on traffic detail added a sense of relief and hope for the guests. And yes, there was food, everything from home baked cookies and snacks, to donated lunches. The volunteers took good care of each other.

Judy shared a story about a volunteer named Valerie, who became a well-known character in the drive through at the Fairgrounds. Many days Valerie brought her own radio with her, an old school boom box, which she positioned on her car, allowing her to have her own 1990s dance party while directing traffic.

One day Valerie came up to me and she said Judy, did you have breakfast? And I said, No, Valerie, I didnt. Valerie responded with a big smile and says Good, because I made you a breakfast sandwich. This is just one example of how weve gone from being strangers to becoming a family of people who look out for one other.

This operation encouraged a lot of couples to volunteer. They just they love it and have befriended other couples, said Mazzella. So many of them missed socializing because of COVID, volunteering gave them something to look forward to that was both productive and meaningful. We all worked so well together and could count on one another to jump in whenever and wherever necessary. So, its been a wonderful experience in so many ways. Knowing that they are making a difference brought them back day after day.

Meet Moya Thompson

When Covid first hit, volunteer opportunities for Moya and her husband came to a standstill. After spending weeks in lockdown, retirees like Moya grew restless, looking for a way to help.

Originally from the Washington, D.C., area, Moya retired from 36 years of government service and moved to Flagler County in 2012. She started working with Flagler Volunteer Services in the countys call center after Hurricane Matthew in 2016, and volunteered for other events as well.

She saw an opportunity to help at the Daytona State College testing site and became a traffic volunteer. In this role, she made sure that cars kept moving and that people knew where they were going. In her opinion, it was a pretty important role.

Ive been doing this for a while, explained Thompson. After being home because of Covid, I just felt that I needed to do something, and this seemed like the perfect way to help.

When the vaccination operation started at the Fairgrounds, Thompson signed up to volunteer there as well.

I started as a traffic volunteer but moved to the area where people fill out consent forms before proceeding to the vaccination tent. Some of these people were elderly. They were a little nervous. They were excited, and they sometimes needed help. So, while we were keeping the cars in line, we took time to talk with the drivers and passengers. We answered questions and tried to make them feel at little more at ease before they made it to the vaccination tent.

Thompson also weighed in on the positive vibe at the Fairgrounds.

The people waiting in line to get their vaccines have been just amazing. Were lucky because we get to see them up close, of course, with our masks on and keeping six feet apart, but we can see the relief on their faces, the excitement, the anticipation of getting the vaccine. Its so rewarding. They talk to you about things that theyre going to do once they get their second dose, and its just a really a feeling of hope, said Thompson. Its a wonderful opportunity to be part of that. As historic as all of this is, its just great to see people looking forward to getting their lives a little bit more back to normal.

Thompson came up with the idea of wearing her collection of crazy hats to the Fairgrounds to make people smile.

On May 24, the final day of vaccinating at the Fairgrounds, Moya posted the following on her Facebook page, along with a few photos:

What a long great trip its been! Since January 2, weve been directing thousands of Flagler County folks toward their Covid-19 vaccinations. Proud to be part of an awesome team (some of whom are featured here) that has helped make Flagler stand out in vaccination rates across Florida. Today was our last day at the Fairgrounds, but vaccines are still widely available across the county. Its been a blast!

Meet Dr. Stephen Playe

Dr. Stephen Playe, a retired Emergency Medicine physician, became part of the Covid-19 vaccination team in January 2021. Hes known Dr. Stephen Bickel, the health departments medical director for 60 years.

A former doctor for Mediquick, Dr. Playe retired in October 2019 and moved to Chicago for several months. Hed remained in touch with Dr. Bickel, but, when he and his wife Ann returned to Flagler, the two Steves became closer, talking most every day by phone, both learning and sharing as much as they could about Covid and its transmission. Dr. Playe described their renewed friendship and joint commitment to understanding more about the virus as an extensive but fascinating learning curve.

We read study after study and spent hours talking about the virus and its connection with biology, politics, economics, sociology, and air flow movements, Playe explained. Right from the beginning, Steve was very excited about working with Bob Snyder and the whole Covid response locally. And, so, it encouraged me to do what I could to help. Early on, most of my role was being a sounding board for a friend who made it his mission to learn as much as he could about this virus. We talked almost every day, and I even helped by writing a letter to the editor of the Palm Coast Observer about mask wearing.

When the vaccination effort started, there was the opportunity to volunteer and be part of it, which I wanted to do. Nearly six months later, its been an excellent experience for me. Part of it is just feeling like youre doing a good thing. Theres something to that. But its been more than that for me because my whole career in medicine has been reactive. When something bad happens to somebody, they come to the emergency department, I try to patch them up or straighten them out or whatever. Its all reactive. This effort, on the other hand, has been preventative. Its a whole different thing and particularly gratifying for me to do something preventative.

Its also been gratifying to interact with people and offer some medical assistance. Ive been one of the four to six medical professionals that would be screening people in cars before they went in to get their vaccination. We wanted to make sure there wasnt some medical contraindication to them getting the vaccine. We determined, from their history, if they should be watched for 15 minutes or 30 minutes after receiving a shot. Sometimes we made mildly complex medical decisions, but most were straightforward. We also answered questions and allayed concerns, and so forth. For the first time in my life, the people that Im interacting with as a doctor are not either miserable, or angry, or both, which is a big part of emergency medicine. This has been a particularly pleasant experience, working with people who are feeling good about what theyre doing. And theyre appreciative of what were doing in return. Thats been nice.

And when I could, I put in a little bit of a plug, especially recently, when we see young people coming through. I tell them how pleased I am they are getting vaccinated, and I thank them for doing something to help themselves and the rest of us. Its about prevention and I ask them to encourage their friends to get vaccinated as well. Again, this is very different from my medical experience. If somebody comes in cardiac arrest and I resuscitate him, I help one person. This vaccine effort has the potential to help many people.

Finally, this large-scale operation reminded me of something I always loved about emergency medicine, working with a whole team. You have your doctors, your residents, your nurses, your techs, your clerks, your orderlies, your police, your EMTs, all these people working together to try to do something good for people. And out there at the fairgrounds, all you have to do is look around and you see that exact same thing. You see volunteers, you see National Guardsmen, you see nurses, doctors, everybody working together to help folks out. Its very much that same kind of sort of magnified joy that you get by doing something with a whole group of people all working together. That was uplifting.

The trials of the last year and a half have shown us who the real heroes are. Our village stepped up. As we move into our new normal, we can honor the people we lost to this virus and help those still recovering. We will work together to rebuild trust and good will in the community. We must if we are to do more than just survive Covid-19. We can thrive in the aftermath. Lets let that be how history remembers us.

Read more:
Volunteers: The Flagler Health Departments Secret Weapon in an Epic Covid Fight - FlaglerLive.com

Posted in Preventative Medicine | Comments Off on Volunteers: The Flagler Health Departments Secret Weapon in an Epic Covid Fight – FlaglerLive.com

Biohaven Showcases CGRP-Antagonist Franchise Data including Nurtec ODT (rimegepant), Now Approved to Treat and Prevent Migraine Attacks, and…

Posted: June 6, 2021 at 2:10 am

NEW HAVEN, Conn., June 3, 2021 /PRNewswire/ --Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 19 abstracts, including one late-breaking presentation and two oral presentations, will be presented at the virtual 63rd Annual Scientific Meeting of the American Headache Society (AHS) being held June 3-6. The presentations will be available to view on the AHS website from June 3, 2021 for one year.

Biohaven will be presenting new and encore data presentations for Nurtec ODT (rimegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist in an orally disintegrating tablet (ODT) approved by the FDA for the acute and preventive treatment of migraine in adults. Nurtec ODT received FDA approval for the preventive treatment of episodic migraine in adults on May 27. Efficacy and safety results from the pivotal Phase 2/3 clinical trial of rimegepant for the preventive treatment for migraine will be presented including data showing a rapid reduction in migraine days. Additionally, posters feature data from the Phase 3 trials and the long-term safety study of rimegepant as an acute treatment for migraine, including in people who have a history of treatment failure with triptans. Health economics and outcomes research analyses shed light on the impact of redosing on cost utility outcomes and demonstrate that the use of rimegepant taken as an acute treatment on an as needed basis over one year was associated with a reduction in monthly migraine days and tablet utilization as well as improved quality of life outcomes. An oral presentation for the Phase 2/3 dose-ranging study of intranasal zavegepant, the only intranasal CGRP receptor antagonist currently in late-stage clinical trials for the acute treatment of migraine, will also be presented.

Elyse Stock, MD, Chief Medical Officer of Biohaven commented, "We continue to build on our deep body of research that demonstrates Nurtec ODT's clinical efficacy and safety for the acute and preventive treatment of migraine. We are energized by the recent FDA approval for Nurtec ODT as a preventive treatment for episodic migraine and are excited to bring forward this oral dual therapy indication to physicians and patients alike. The clinical and health economics data presented at AHS emphasize this paradigm changing treatment approach as the first and only medication that can treat and prevent migraine attacks."

Notable highlights include:

The complete list of accepted abstract titles is below and full presentations will be available on the 2021 AHS virtual annual meeting website beginning June 3, 2021.

Oral Presentations:

Late-Breaking Poster Presentation:

Poster Presentations:

About NURTEC ODTNURTEC ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a quick-dissolve ODT formulation that is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine with or without aura and the preventive treatment of episodic migraine in adults. The activity of the neuropeptide CGRP is thought to play a causal role in migraine pathophysiology. NURTEC ODT is a CGRP receptor antagonist that works by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide. The recommended dose of NURTEC ODT is 75 mg, taken as needed, up to once daily to treat or every other day to help prevent migraine attacks. For more information about NURTEC ODT, visit http://www.nurtec.com. The most common adverse reaction was nausea and abdominal pain/indigestion. Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of NURTEC ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

IndicationNURTEC ODT orally disintegrating tablets is a prescription medicine that is used to treat migraine in adults. It is for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine. It is not known if NURTEC ODT is safe and effective in children.

Important Safety InformationDo not take NURTEC ODT if youare allergic to NURTEC ODT (rimegepant) or any of its ingredients.

Before you take NURTEC ODT, tell your healthcare provider (HCP) about all your medical conditions, including if you:

Tell your HCP about all the medicines you take,including prescription and over-the-counter medicines, vitamins, and herbal supplements.

NURTEC ODT may cause serious side effects including allergic reactions, including trouble breathing and rash. This can happen days after you take NURTEC ODT. Call your HCP or get emergency help right away if you have swelling of the face, mouth, tongue, or throat or trouble breathing. This occurred in less than 1% of patients treated with NURTEC ODT.

The most common side effects of NURTEC ODT were nausea (2.7%) and stomach pain/indigestion (2.4%). These are not the only possible side effects of NURTEC ODT. Tell your HCP if you have any side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatchor call1800FDA1088or report side effects to Biohaven at18334NURTEC.

Please click here for fullPrescribing InformationandPatient Information.

About ZavegepantZavegepant is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist from Biohaven's NOJECTION Migraine Platform and the only CGRP receptor antagonist in clinical development with both intranasal and oral formulations. The efficacy and safety profile of intranasal zavegepant for the acute treatment of migraine, as compared to placebo, was shown in a randomized controlled Phase 2/3 dose-ranging trial with a total of over 1000 patients who received zavegepant. In this study, zavegepant showed statistical superiority to placebo on the coprimary endpoints of 2 hour freedom from pain and freedom from a patients' most bothersome symptom (either nausea, photophobia or phonophobia). Following successful end of Phase 2 interactions with FDA (clinical and nonclinical), zavegepant is advancing to Phase 3 for the acute treatment of migraine in adults. For more information, visithttps://www.biohavenpharma.com/science-pipeline/cgrp/bhv-3500.

About BiohavenBiohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis. More information about Biohaven is available atwww.biohavenpharma.com.

Forward-looking StatementThis news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe", "may" and "will" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of Biohaven's management about NURTEC ODT as an acute or preventative treatment for patients with migraine. Forward-looking statements include those related to: Biohaven's ability to effectively commercialize NURTEC ODT, delays or problems in the supply or manufacture of NURTEC ODT, complying with applicableU.S.regulatory requirements, the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials, the timing of planned interactions and filings with the FDA, the timing and outcome of expected regulatory filings, the potential commercialization of Biohaven's product candidates, the potential for Biohaven's product candidates to be first in class or best in class therapies and the effectiveness and safety of Biohaven's product candidates. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Additional important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021. The forward-looking statements are made as of this date and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

NURTEC and NURTEC ODT are registered trademarks of Biohaven Pharmaceutical Ireland DAC.

Neuroinnovation and NOJECTION are trademarks of Biohaven Pharmaceutical Holding Company Ltd.

Biohaven ContactDr. Vlad CoricChief Executive Officer[emailprotected]

Media ContactMike BeyerSam Brown Inc.[emailprotected] 312-961-2502

SOURCE Biohaven Pharmaceutical Holding Company Ltd.

http://biohavenpharma.com

Link:
Biohaven Showcases CGRP-Antagonist Franchise Data including Nurtec ODT (rimegepant), Now Approved to Treat and Prevent Migraine Attacks, and...

Posted in Preventative Medicine | Comments Off on Biohaven Showcases CGRP-Antagonist Franchise Data including Nurtec ODT (rimegepant), Now Approved to Treat and Prevent Migraine Attacks, and…

Biotechnology Execs Discuss the Industrys Impact on Beauty – Yahoo Lifestyle

Posted: June 6, 2021 at 2:08 am

As brands and consumers alike seek out innovation, biotechnology and beauty are increasingly intertwining.

During Beauty Inc @20, Alex Lorestani, chief executive officer and cofounder of Geltor; John Melo, CEO of Amyris, and Barbara Paldus, CEO and founder of Codex Beauty spoke about biotechs impact on beauty with WWDs senior editor Allison Collins.

More from WWD

For Amyris, its lab-produced squalane has become the companys bread and butter. Were about 70 percent of the world market for squalane, and were expanding the market by 25 percent per year, Melo said. Our sales are growing at about 40 percent per year, and were selling squalane to about 3,000 beauty brands around the world.

Geltor, for its part, produces collagen that is identical to human collagen, and it, too, is tracking upticks in interest. Customers and consumers are beginning to understand what you can really get from biology, its becoming more of an opportunity driver, Lorestani said.

Paldus, who came from a professional background in biotechnology, founded Codex Beauty after the birth of her son. I couldnt find preservative systems that werent fossil fuel-based, she said. Thats how we ended up with biotech ingredients; we were looking for ferments that could actually act as a preservative system.

Sustainability was a major theme, too, as lab-grown alternatives can cause less environmental damage than other sourcing methods. We save 3 million sharks a year with squalane were making through fermentation. Sustainability starts with this idea that once you kill the shark, youre not going to produce any more squalene from that shark. Ours we make from sugarcane, which is a five-year crop, Melo said.

The case was the same with Geltor. We had a third-party perform a lifecycle analysis and we could show that it required 79 percent less water, 50 percent less greenhouse gas and requires 40 percent less land to make proteins through fermentation, Lorestani said.

Story continues

The thing with biotechnology today is it can deliver anything across the spectrum, he continued. Theres a really exciting spectrum of products to have and were seeing more and more third-party entities emerge to certify different kinds of products.

Amyris value proposition is two-pronged: not only are ingredients less impactful environmentally, theyre also less expensive, 30 percent less than alternative sources, according to Melo. As we learn about the consumer and the purpose we have for them, theyre all for sustainability. So, it needs to perform as well, or better, then the alternative source, he said. Cost has to be at least the same, or better.

During the Q&A, Paldus said communicating around biotechnology requires a lot of consumer education. Biotechnology is actually natural the proteins and stem cells are 100 percent equivalent to those extracted from plants. Biotech is actually natural 2.0, because youre getting sustainable ingredients that havent been exposed to pollution, she said. These ingredients also often perform better, because theyre undiluted.

FOR MORE FROM WWD.COM, SEE:

Amyris Partners With I Am That Girl

The 11 Best Collagen Powders for Firm, Glowing Skin

The 14 Best Collagen Serums for Enhanced Firmness and Wrinkle Reduction

Sign up for WWD's Newsletter. For the latest news, follow us on Twitter, Facebook, and Instagram.

See the original post here:
Biotechnology Execs Discuss the Industrys Impact on Beauty - Yahoo Lifestyle

Posted in Biotechnology | Comments Off on Biotechnology Execs Discuss the Industrys Impact on Beauty – Yahoo Lifestyle

Is IVERIC bio Inc (ISEE) a Leader in the Biotechnology Industry? – InvestorsObserver

Posted: June 6, 2021 at 2:08 am

IVERIC bio Inc (ISEE) is around the top of the Biotechnology industry according to InvestorsObserver. ISEE received an overall rating of 72, which means that it scores higher than 72 percent of all stocks. IVERIC bio Inc also achieved a score of 98 in the Biotechnology industry, putting it above 98 percent of Biotechnology stocks. Biotechnology is ranked 107 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 72 means the stock is more attractive than 72 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

IVERIC bio Inc (ISEE) stock is down -3.8% while the S&P 500 has gained 0.88% as of 2:34 PM on Friday, Jun 4. ISEE is down -$0.26 from the previous closing price of $6.84 on volume of 269,144 shares. Over the past year the S&P 500 has gained 35.90% while ISEE has gained 65.74%. ISEE lost -$1.16 per share the over the last 12 months.

Click Here to get the full Stock Score Report on IVERIC bio Inc (ISEE) Stock.

Continued here:
Is IVERIC bio Inc (ISEE) a Leader in the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is IVERIC bio Inc (ISEE) a Leader in the Biotechnology Industry? – InvestorsObserver

Should You Hold Halozyme Therapeutics, Inc. (HALO) in Biotechnology Industry? – InvestorsObserver

Posted: June 6, 2021 at 2:08 am

Halozyme Therapeutics, Inc. (HALO) is around the middle of the Biotechnology industry according to InvestorsObserver. HALO received an overall rating of 36, which means that it scores higher than 36 percent of all stocks. Halozyme Therapeutics, Inc. also achieved a score of 48 in the Biotechnology industry, putting it above 48 percent of Biotechnology stocks. Biotechnology is ranked 107 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 36 would rank higher than 36 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Halozyme Therapeutics, Inc. (HALO) stock is trading at $39.53 as of 2:35 PM on Friday, Jun 4, a rise of $0.69, or 1.79% from the previous closing price of $38.84. The stock has traded between $39.10 and $39.78 so far today. Volume today is below average. So far 399,257 shares have traded compared to average volume of 953,640 shares.

Click Here to get the full Stock Score Report on Halozyme Therapeutics, Inc. (HALO) Stock.

View original post here:
Should You Hold Halozyme Therapeutics, Inc. (HALO) in Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Should You Hold Halozyme Therapeutics, Inc. (HALO) in Biotechnology Industry? – InvestorsObserver

Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference – Yahoo Finance

Posted: June 6, 2021 at 2:08 am

SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9th at 12:00 pm PT / 3:00 pm ET.

A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at http://www.vir.bio and will be archived there following the presentation for 30 days.

The Company has used, and intends to continue to use, the Investors page of its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Companys Investors website, in addition to following the Companys press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.

About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit http://www.vir.bio.

Original post:
Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference - Yahoo Finance

Posted in Biotechnology | Comments Off on Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference – Yahoo Finance

Where Does Salarius Pharmaceuticals Inc (SLRX) Stock Fall in the Biotechnology Field After It Is Up 12.30% This Week? – InvestorsObserver

Posted: June 6, 2021 at 2:08 am

A rating of 91 puts Salarius Pharmaceuticals Inc (SLRX) near the top of the Biotechnology industry according to InvestorsObserver. Salarius Pharmaceuticals Inc's score of 91 means it scores higher than 91% of stocks in the industry. Salarius Pharmaceuticals Inc also received an overall rating of 57, putting it above 57% of all stocks. Biotechnology is ranked 109 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Salarius Pharmaceuticals Inc (SLRX) stock is higher by 3.02% while the S&P 500 is lower by -0.91% as of 9:52 AM on Thursday, Jun 3. SLRX is up $0.04 from the previous closing price of $1.33 on volume of 640,392 shares. Over the past year the S&P 500 is up 33.53% while SLRX is up 12.30%. SLRX lost -$0.42 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Salarius Pharmaceuticals Inc (SLRX) Stock.

See the article here:
Where Does Salarius Pharmaceuticals Inc (SLRX) Stock Fall in the Biotechnology Field After It Is Up 12.30% This Week? - InvestorsObserver

Posted in Biotechnology | Comments Off on Where Does Salarius Pharmaceuticals Inc (SLRX) Stock Fall in the Biotechnology Field After It Is Up 12.30% This Week? – InvestorsObserver

Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors – Business Wire

Posted: June 6, 2021 at 2:08 am

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Michael F. MacLean, chief financial officer (CFO) of Avidity Biosciences, has joined the companys board of directors.

Mike is a highly experienced executive with an established track record of leading financial strategy and execution for a number of life science companies, as well as other industries. His experience will be incredibly valuable to Verve and our evolution toward clinical development, said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. We look forward to leveraging his insights and knowledge of best practices for financial operations at growing biotechnology companies as we continue to advance our pipeline.

Verves targeted approach to addressing the causal drivers of cardiovascular disease through single-course gene editing medicines holds significant promise to transforming treatment for people with this highly prevalent and life-threatening disease, said Mr. MacLean. I have been impressed by the progress the company has been making, led by an exceptional team of individuals, and am pleased to partner with them to help support the continued growth of the company.

Mr. MacLean has more than 30 years of experience in financial leadership roles in the life sciences and other industries. In addition, he has been a key player in strategy and operations for high growth companies. He joined Avidity Biosciences as CFO prior to its IPO in June 2020. Prior to Avidity, he served as CFO of Akcea Therapeutics, Inc., where he led the buildout of Akcea's financial and commercial infrastructure, and was the CFO of PureTech Health, plc. Previously, he led Biogens worldwide finance operations. Earlier in his career, Mr. MacLean was an audit partner at KPMG and Andersen.

About Verve Therapeutics

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The companys initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verves lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patients risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, please visit http://www.VerveTx.com.

More here:
Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors - Business Wire

Posted in Biotechnology | Comments Off on Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors – Business Wire

Attend the Biotechnology, Chemical and Pharmaceutical (BCP) Partnership meeting – United States Patent and Trademark Office

Posted: June 6, 2021 at 2:08 am

Share your insights and experiences to improve patent prosecution in biotechnology areas at the USPTOs next Biotechnology, Chemical and Pharmaceutical Customer Partnership (BCP) meeting. The meeting will be held virtually.

Register for this event.

BCP meetings are part of a long-standing partnership between the USPTO and its valued stakeholders. The partnership works to improve the quality of the agencys products and services. The meeting willdiscuss:

Date and Location:

Day 1: Tuesday, June 15, 2021, 1 - 5p.m. ET; Online

Day 2: Wednesday, June 16, 2021, 12:30 - 5p.m. ET; Online

BCP agenda

The USPTO looks forward to hearing from its customers and does not intend to use this forum to seek or arrive at any consensus.

For questions and comments regarding this event, please email: USPTOBCP1600@USPTO.GOV

See the original post here:
Attend the Biotechnology, Chemical and Pharmaceutical (BCP) Partnership meeting - United States Patent and Trademark Office

Posted in Biotechnology | Comments Off on Attend the Biotechnology, Chemical and Pharmaceutical (BCP) Partnership meeting – United States Patent and Trademark Office

Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for…

Posted: June 6, 2021 at 2:08 am

HOUSTON and SAN DIEGO, June 1, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-mediated gene therapies for the treatment of ocular diseases, and Hopstem Biotechnology, the leading human induced pluripotent stem cell (hiPSC) and neural differentiation technology platform company, today announced a strategic partnership aiming to provide human iPSC-derived cell therapy for ocular diseases.

The partnership leverages Neurophth's experience in global gene/cell therapy drugs development and understanding of ophthalmic diseases to complement Hopstem's expertise in GMP manufacturing and quality assurance of iPSC-derived clinical cell products to provide next-generation ocular treatments. Under the terms of agreement, Hopstem Biotechnology will receive upfront and milestone payments for the development of candidate cell product for agreed retinal degenerative disorder. Neurophth will have the option to license the candidate product and will be responsible for development and commercialization of the licensed product. In addition, Neurophth agreed to license Hopstem's iPSC reprogramming patent and GMP iPSC line with additional payments to Hopstem at different product development stages. According to the agreement, Hopstem will also share part of the product sales.

"This collaboration exemplifies Neurophth's long-term commitment to advancing the field of ophthalmic treatment as we continue to expand and progress our innovative pipeline of ocular candidates," said Bin Li, M.D., Ph.D., Founder and Chairman of Neurophth Therapeutics. "Combining the methods of stem cell technology, induced pluripotent stem cells is a promising technology that can offer an extraordinary potential for regenerative therapy, disease modeling and drug screening."

"We are very excited by this partnership with Neurophth. The human induced pluripotent stem cell (hiPSC) line we developed is made by transforming the skin of a healthy donor into stem cells that are capable of multiplying and becoming any type of cell in the human body, meeting GMP requirements. Thanks to our iPSC-derived clinical cell product manufactory and quality platform developed since 2019, we are able to speed up ocular cell product development with Neurophth, the leading ocular therapy company in the field. Together, our aim is to offer safe and effective regenerative medicine with hiPSC-derived cellsfor reversing the progression of ocular diseases and restoring vision for patients," Jing Fan, Ph.D., Founder and CEO of Hopstem Biotechnology.

"iPSCs holds the promise for treatment of retinal degenerative disorders where AAV-mediated gene therapy is unreachable," said Alvin Luk, Ph.D., M.B.A., CEO at Neurophth. "Hopstem is one of the most respected pioneers in the field of iPSC translational medicine. We are confident that their technology and expertise, combined with Neurophth's deep knowledge in ophthalmology and drug development, has the potential to unlock future generations of gene/cell therapy treatments for patients."

About Neurophth

Neurophth is China's first gene therapy company for ophthalmic diseases. Headquartered in Wuhan with subsidiaries in Shanghai, Suzhou, and US, Neurophth, a fully integrated company, is striving to discover and develop gene therapies for patients suffering from blindness and other eye diseases globally. Our validated AAV platform which has been published in Nature - Scientific Reports, Ophthalmology, and EBioMedicine, has successfully delivered proof-of-concept data with investigational gene therapies in the retina. Our most advanced investigational candidate, NR082 (NFS-01 project, rAAV2-ND4), in development for the treatment ofND4-mediated Leber hereditary optic neuropathy (LHON), has granted orphan designation by theU.S FDA and its IND has also been approved by China NMPA. The pipeline also includesND1-mediated LHON, autosomal dominant optic atrophy, optic neuroprotection (e.g., glaucoma), vascular retinopathy (e.g., diabetic macular edema and wet age-related macular degeneration), and five other preclinical candidates. Neurophth has initiated the scaling up in-house manufacturing process in single-use technologies to support future commercial demand at the Suzhou facility. To learn more about us and our growing pipeline, please visitwww.neurophth.com.

About Hopstem

Hopstem Biotechnology is one of the first few iPSC cell therapy companies in China. The company was founded in January 2017 in Hangzhou (China) and Baltimore (US) by neuroscientists and stem-cell biologists from Johns Hopkins University. Hopstem has established a world-leading neural differentiation platform as well as patented iPSC reprogramming method and high standard GMP manufactory and quality system. The mission of Hopstem is to apply these cutting-edge technologies to develop innovative cell therapies for CNS and other disorders. Our leading clinical product, hNPC01, is a human forebrain neural progenitor cell product for stroke and traumatic brain injuries, etc. Preliminary studies in rat and monkey pMCAO stroke models have suggested that majority of those transplanted hNPCs differentiated into functional neural cells and formed significant new connections with the rat neurons in distal regions. To learn more about us, please visit http://www.hopstem.com.

View original content:http://www.prnewswire.com/news-releases/neurophth-therapeutics-and-hopstem-biotechnology-announce-strategic-partnership-to-develop-human-induced-pluripotent-stem-cell-derived-therapies-for-the-treatment-of-ocular-diseases-301302715.html

SOURCE Neurophth Therapeutics, Inc.

Read the rest here:
Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for...

Posted in Biotechnology | Comments Off on Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for…

Page 734«..1020..733734735736..740750..»